Really interesting early results from the FLAIR trial!
Unmutated patients respond better to Ibrutinib... - CLL Support
Unmutated patients respond better to Ibrutinib/Venetoclax compared to mutated
Written by
Greenbunnies
To view profiles and participate in discussions please or .
Read more about...
3 Replies
•
I was thrilled when I read this very surprising report. Being unmutated, I always felt less hope for treatment success compared to those who are mutated. I am a bit in disbelief if it is true. So glad more and more therapies/options are becoming available!
Adrian Bloor told me my FISH results on Friday but he kept reminding me of how quickly I responded to treatment and that I was fortunate to be randomised V& I since ‘we’ seem to respond well.
The numbers are convincing: In this trial, unmutated patients treated with Ibrutinib + Venetoclax tended to achieve uMRD faster, whether measured in peripheral blood or bone marrow.
IMO only if these patients enjoy a remission at least as long as their mutated counterparts' will it become clear that their response to treatment was "better". But I hope that both sets of patients will achieve very long remissions with this synergistic combination.
